企業プロフィール
AnaptysBio, Inc. 株価・ニュース・カタリスト
- ティッカー:
- ANAB
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
59.69 USD (+2.09%)
終値
最終更新: 2026年8月17日
1.49B USD
時価総額
株価変動の要因
As of Aug 17, 2026, ANAB closed up 2.09% at $59.69. No new same-company headline was identified in the current news window.
企業概要
Biopharma Royalty Company
Following the spin-off of First Tracks Biotherapeutics, AnaptysBio manages financial collaborations rather than operating an internal drug-development portfolio.
Jemperli Economics
Anaptys receives royalties tied to GSK’s Jemperli franchise, including development in endometrial, rectal, colon, and head and neck cancers.
Imsidolimab Economics
The company also retains financial exposure to Vanda’s imsidolimab program in generalized pustular psoriasis.
今後のカタリスト
- Data from the pivotal AZUR-1 study of Jemperli in locally advanced rectal cancer are expected in the second half of 2026.
- Data from the Phase 2 AZUR-4 colon cancer study are expected in the fourth quarter of 2026.
- The FDA PDUFA action date for imsidolimab in generalized pustular psoriasis is December 12, 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。